Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
14.86 EUR | -1.59% | +5.24% | +51.32% |
Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+51.32% | 1.02B | |
+4.09% | 43.84B | |
+9.45% | 41.68B | |
+45.55% | 41.25B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+1.28% | 12.29B | |
+29.70% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- Abivax's Ulcerative Colitis Drug Gets EU Agency Support to Proceed to Late-Stage Testing